Drug & intervention

panobinostat

RxCUI 1603350

Clinical trials13
Recruiting0
Related conditions20
Synonyms9

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

13 shown
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
PDR001 + Panobinostat for Melanoma and NSCLCNCT03982134 · 2019-09-01
WITHDRAWN
A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNCT02890069 · 2016-10-14
COMPLETED
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyNCT02471430 · 2016-05-01
COMPLETED
CINC424A2X01B Rollover ProtocolNCT02386800 · 2015-03-05
ACTIVE_NOT_RECRUITING
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAARTNCT01680094 · 2012-09-01
COMPLETED
Panobinostat and Letrozole in Treating Patients With Metastatic Breast CancerNCT01105312 · 2010-09-01
COMPLETED
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT01160731 · 2009-11-01
WITHDRAWN
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After CastrationNCT00878436 · 2009-06-01
COMPLETED
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast CancerNCT00777049 · 2009-02-01
COMPLETED
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck CancerNCT00670553 · 2008-09-01
COMPLETED
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After TrastuzumabNCT00567879 · 2008-04-01
TERMINATED
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerNCT00667862 · 2008-03-18
COMPLETED

Conditions being studied

Breast Cancer3Prostate Cancer3HIV Infection2Primary Myelofibrosis2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Acute Myeloid Leukemia1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Castration-Resistant Prostate Carcinoma1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma1Esophageal Cancer1Graft Versus Host Disease1Head & Neck Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.